罗格列酮对2型糖尿病患者尿白蛋白的影响

The effects of rosiglitazone on albuminuria in type 2 diabetic patients

目的应用罗格列酮(RGZ)治疗2型糖尿病(T2DM)早期肾病患者,观察尿白蛋白及纤维蛋白原(Fib)、C反应蛋白(C-RP)的变化。方法 T2DM早期肾病患者[尿白蛋白排泄率(UAER)20～200μg/min]60例,随机分为RGZ治疗组及非RGZ治疗组,各30例,测定血糖、血脂、UAER、C-RP、Fib、FIns及HOMA-IR等。另选30名健康者和30例单纯T2DM患者作对照。结果 RGZ治疗组和非RGZ治疗组治疗后,血糖、TG、FIns、HOMA-IR、C-RP、Fib、UAER均较治疗前下降,治疗后两组间比较差异有统计学意义(P<0.01)。HDL-C治疗后逐渐升高,与非RGZ治疗组比较差异有统计学意义(P<0.05)。结论 RGZ可缓解胰岛素抵抗,在有效降低血糖、TG、C-RP、Fib水平的同时,降低UAER水平,使用罗格列酮进行干预可有效减轻糖尿病肾病患者白蛋白尿。

Objective To study the effect of rosiglitazone on albuminuria in type 2 diabetic patients. Methods The sixty early diabetic nephropathy patients were randomly divided into two groups treated with （n = 30,RGZ）and without（n= 30, control） rosiglitazone. Meanwhile, 30 healthy people were selected for the normal control（NC）. In all of the patients, levels of glucose, lipid, UAER, C-RP, Fib, fastin insulin（Fins） and homeostatic model assessment of insulin resistance（HOMA-IR） were examined. Results In RGZ versus non-RGZ gruop at 6-month treatment, the levels of glucose, HbAlc, TG, Fins, HOMA-IR,C RP, Fib, UAER were decreased obviously（P〈0. 05）,and the level of HDL-C was increased （P〈0.05）. Conclusions Rosiglitazone can relieve insulin resistance,decrease plasma levels of glucose, TG, and increase HDL efficiently. Besides, it can decrease the level of C-RP, Fib,and UAER. The using of rosiglitazone in DN patients can lessen abnormal albuminuria.